Black Diamond Therapeutics Inc [BDTX] stock is trading at $4.79, up 5.51%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BDTX shares have gain 17.98% over the last week, with a monthly amount drifted -1.44%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC.
From an analyst’s perspective:
Previously, Stifel upgraded its rating to Buy on June 30, 2023, and elevated its price target to $10. On June 28, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $11 on the stock. Wedbush upgraded its rating to a Outperform but stick to its price target of $10 on June 27, 2023. Wedbush downgraded its rating to a Neutral. H.C. Wainwright downgraded its rating to Neutral for this stock on March 22, 2022. In a note dated September 30, 2021, Stifel initiated an Hold rating and provided a target price of $10 on this stock.
Black Diamond Therapeutics Inc [BDTX] stock has fluctuated between $1.43 and $6.85 over the past year. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $4.79 at the most recent close of the market.
Analyzing the BDTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is 14.46 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.53 points at the first support level, and at 4.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.03, and for the 2nd resistance point, it is at 5.28.
Black Diamond Therapeutics Inc [BDTX] reported earnings per share of -$0.34 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.47/share, meaning a difference of $0.13 and a surprise factor of 27.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.45 per share as compared to estimates of -$0.49 per share, a difference of $0.04 representing a surprise of 8.20%.
Ratios To Look Out For
For context, Black Diamond Therapeutics Inc’s Current Ratio is 6.82. As well, the Quick Ratio is 6.82, while the Cash Ratio is 2.86.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Oct 17 ’23 when 0.4 million shares were purchased. Director, Behbahani Ali completed a deal on Jul 05 ’23 to buy 1.0 million shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 0.94 million shares on Jul 05 ’23.
